# EDGAR Filing Document

**Accession Number:** 0001704131
**File Stem:** 0001193125-26-038168
**Filing Date:** 2026-2
**Character Count:** 22993
**Document Hash:** d1efbaee9a04dd331aef922e782cf48e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-038168.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001193125-26-038168

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260204

**FILED AS OF DATE**: 20260204

**DATE AS OF CHANGE**: 20260204

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital Fund IV, L.P.
- **CENTRAL INDEX KEY:** 0001704131

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600190

**BUSINESS ADDRESS:**
- **STREET 1:** 600 MONTGOMERY STREET, SUITE 4500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** 415-877-4887

**MAIL ADDRESS:**
- **STREET 1:** 600 MONTGOMERY STREET, SUITE 4500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital Management IV, LLC
- **CENTRAL INDEX KEY:** 0001704132

**ORGANIZATION NAME:**
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600191

**BUSINESS ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
- **BUSINESS PHONE:** 415-877-4887

**MAIL ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital Fund V, L.P.
- **CENTRAL INDEX KEY:** 0001792204

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600189

**BUSINESS ADDRESS:**
- **STREET 1:** 600 MONTGOMERY STREET, SUITE 4500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** 415-877-4887

**MAIL ADDRESS:**
- **STREET 1:** 600 MONTGOMERY STREET, SUITE 4500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital Opportunity Fund V, L.P.
- **CENTRAL INDEX KEY:** 0001792205

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600187

**BUSINESS ADDRESS:**
- **STREET 1:** 600 MONTGOMERY STREET, SUITE 4500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** 415-877-4887

**MAIL ADDRESS:**
- **STREET 1:** 600 MONTGOMERY STREET, SUITE 4500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital VI-A Management, LLC
- **CENTRAL INDEX KEY:** 0001899218

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600184

**BUSINESS ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
- **BUSINESS PHONE:** 415-877-4887

**MAIL ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital Opportunity Management V, LLC
- **CENTRAL INDEX KEY:** 0001792207

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600186

**BUSINESS ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
- **BUSINESS PHONE:** 415-877-4887

**MAIL ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital Management V, LLC
- **CENTRAL INDEX KEY:** 0001792206

**ORGANIZATION NAME:**
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600188

**BUSINESS ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
- **BUSINESS PHONE:** 415-877-4887

**MAIL ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Foresite Capital VI-A, LLC
- **CENTRAL INDEX KEY:** 0001899120

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600185

**BUSINESS ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
- **BUSINESS PHONE:** 4158774887

**MAIL ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE, SUITE 150
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eikon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001861123
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842807586
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030
- **BUSINESS PHONE:** 341-777-0566

**MAIL ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital Management IV, LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital Fund IV, L.P.<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital Fund V, L.P.<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital Management V, LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital Opportunity Fund V, L.P.<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital Opportunity Management V, LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital VI-A, LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Foresite Capital VI-A Management, LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O FORESITE CAPITAL MANAGEMENT<br>9200 SUNSET BLVD SUITE 515<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 1340878 | <sup>(1)</sup> | I | See footnote<sup>(2)</sup> |
| Series A-1 Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 335521 | <sup>(3)</sup> | I | See footnote<sup>(2)</sup> |
| Series A-1 Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 697885 | <sup>(3)</sup> | I | See footnote<sup>(4)</sup> |
| Series A-1 Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 348942 | <sup>(3)</sup> | I | See footnote<sup>(5)</sup> |
| Series B-1 Preferred Stock | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 37855 | <sup>(6)</sup> | I | See footnote<sup>(2)</sup> |
| Series B-1 Preferred Stock | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 37855 | <sup>(6)</sup> | I | See footnote<sup>(4)</sup> |
| Series B-1 Preferred Stock | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 37855 | <sup>(6)</sup> | I | See footnote<sup>(5)</sup> |
| Series B-1 Preferred Stock | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 408725 | <sup>(6)</sup> | I | See footnote<sup>(7)</sup> |
| Series C Preferred Stock | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 1626 | <sup>(8)</sup> | I | See footnote<sup>(4)</sup> |
| Series C Preferred Stock | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 922 | <sup>(8)</sup> | I | See footnote<sup>(5)</sup> |
| Series C-1 Preferred Stock | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 67207 | <sup>(9)</sup> | I | See footnote<sup>(4)</sup> |
| Series C-1 Preferred Stock | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 38133 | <sup>(9)</sup> | I | See footnote<sup>(5)</sup> |
| Series D Preferred Stock | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 229428 | <sup>(10)</sup> | I | See footnote<sup>(2)</sup> |
| Series D Preferred Stock | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 458855 | <sup>(10)</sup> | I | See footnote<sup>(4)</sup> |
| Warrants | 2025-02-14 | 2030-02-14 | Common Stock | 17092 | $43.59 | I | See footnote<sup>(2)</sup> |
| Warrants | 2025-02-14 | 2030-02-14 | Common Stock | 34185 | $43.59 | I | See footnote<sup>(4)</sup> |

---

### Footnotes:

(1) The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.

(2) The shares are held by Foresite Capital Fund IV, L.P ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over the securities held by Fund IV. James B. Tananbaum is the managing member of FCM IV and may be deemed to share voting and dispositive power over such securities. Each of the Reporting Persons disclaims the existence of a "group," as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

(3) The Series A-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.

(4) The shares are held by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. James B. Tananbaum is the managing member of FCM V and may be deemed to share voting and dispositive power over such securities. Each of the Reporting Persons disclaims the existence of a "group," as defined in Rule 13d-5 of the Exchange Act, and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

(5) The shares are held by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. James B. Tananbaum is the managing member of FCOM V and may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group," as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

(6) The Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.

(7) The shares are held by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the managing member of Fund VI-A and may be deemed to have sole voting and dispositive power over the shares held by Fund VI-A. James B. Tananbaum is the managing member of FC VI-A Management and may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group," as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.

(8) The Series C Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.

(9) The Series C-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.

(10) The Series D Preferred Stock is convertible into Common Stock on a 1-for 7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series D Preferred Stock will be converted into shares of Common Stock of the Issuer.

**Signature:** Foresite Capital Fund IV, L.P., By: Foresite Capital Management IV, LLC, its General Partner, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

**Signature:** Foresite Capital Management IV, LLC, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

**Signature:** Foresite Capital Fund V, L.P., By: Foresite Capital Management V, LLC, its General Partner, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

**Signature:** Foresite Capital Management V, LLC, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

**Signature:** Foresite Capital Opportunity Fund V, L.P., By: Foresite Capital Opportunity Management V, LLC, its General Partner, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

**Signature:** Foresite Capital Opportunity Management V, LLC, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

**Signature:** Foresite Capital Fund VI-A, LLC, By: Foresite Capital VI-A Management, LLC, its General Partner, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

**Signature:** Foresite Capital VI-A Management, LLC, By: James B. Tananbaum, Managing Member /s/ James B. Tananbaum  
**Date:** 2026-02-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**